Natural cytotoxicity in breast cancer patients receiving neoadjuvant chemotherapy

Effects of L-arginine supplementation

J. Brittenden*, S. D. Heys, J. Ross, K. G.M. Park, O. Eremin

*Corresponding author for this work

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Certain cytotoxic drugs have been shown to suppress host anti-cancer defence mechanisms. The amino acid L-arginine can significantly enhance natural killer (NK) and lymphokine-activated killer (LAK) cell cytotoxicity in patients with locally advanced breast cancer. In this study, the effect of L-arginine supplementation on natural cytotoxicity was determined in patients with breast cancer receiving CHOP chemotherapy. This cytotoxic regimen caused a transient immunosuppression, maximal on day 14 of each cycle (P < 0.001); this was not cumulative during the four cycles of treatment. Those patients receiving L-arginine supplementation (30 g/day for 3 days prior to each course of chemotherapy) had a smaller and delayed onset of immunosuppression (day 14), compared with those patients who had CHOP only (day 9). L-Arginine was able to repeatedly stimulate NK and LAK cell cytotoxicity in patients who were receiving CHOP chemotherapy (P < 0.003). In conclusion further studies are required to determine the optimal use of chemotherapeutic agents, alone or in combination with immunostimulators, to avoid inhibition of host anti-cancer defence mechanisms.

Original languageEnglish
Pages (from-to)467-472
Number of pages6
JournalEuropean Journal of Surgical Oncology
Volume20
Issue number4
Publication statusPublished - Aug 1994

Fingerprint

Arginine
Breast Neoplasms
Drug Therapy
Lymphokine-Activated Killer Cells
Immunosuppression
Neoplasms
Amino Acids
Pharmaceutical Preparations
Therapeutics

Keywords

  • Antineoplastic agents
  • Arginine
  • Breast neoplasm
  • Cytotoxicity (immunologic)

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Natural cytotoxicity in breast cancer patients receiving neoadjuvant chemotherapy : Effects of L-arginine supplementation. / Brittenden, J.; Heys, S. D.; Ross, J.; Park, K. G.M.; Eremin, O.

In: European Journal of Surgical Oncology, Vol. 20, No. 4, 08.1994, p. 467-472.

Research output: Contribution to journalArticle

@article{f18dff732abc427baa6f64208eb7b716,
title = "Natural cytotoxicity in breast cancer patients receiving neoadjuvant chemotherapy: Effects of L-arginine supplementation",
abstract = "Certain cytotoxic drugs have been shown to suppress host anti-cancer defence mechanisms. The amino acid L-arginine can significantly enhance natural killer (NK) and lymphokine-activated killer (LAK) cell cytotoxicity in patients with locally advanced breast cancer. In this study, the effect of L-arginine supplementation on natural cytotoxicity was determined in patients with breast cancer receiving CHOP chemotherapy. This cytotoxic regimen caused a transient immunosuppression, maximal on day 14 of each cycle (P < 0.001); this was not cumulative during the four cycles of treatment. Those patients receiving L-arginine supplementation (30 g/day for 3 days prior to each course of chemotherapy) had a smaller and delayed onset of immunosuppression (day 14), compared with those patients who had CHOP only (day 9). L-Arginine was able to repeatedly stimulate NK and LAK cell cytotoxicity in patients who were receiving CHOP chemotherapy (P < 0.003). In conclusion further studies are required to determine the optimal use of chemotherapeutic agents, alone or in combination with immunostimulators, to avoid inhibition of host anti-cancer defence mechanisms.",
keywords = "Antineoplastic agents, Arginine, Breast neoplasm, Cytotoxicity (immunologic)",
author = "J. Brittenden and Heys, {S. D.} and J. Ross and Park, {K. G.M.} and O. Eremin",
year = "1994",
month = "8",
language = "English",
volume = "20",
pages = "467--472",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Natural cytotoxicity in breast cancer patients receiving neoadjuvant chemotherapy

T2 - Effects of L-arginine supplementation

AU - Brittenden, J.

AU - Heys, S. D.

AU - Ross, J.

AU - Park, K. G.M.

AU - Eremin, O.

PY - 1994/8

Y1 - 1994/8

N2 - Certain cytotoxic drugs have been shown to suppress host anti-cancer defence mechanisms. The amino acid L-arginine can significantly enhance natural killer (NK) and lymphokine-activated killer (LAK) cell cytotoxicity in patients with locally advanced breast cancer. In this study, the effect of L-arginine supplementation on natural cytotoxicity was determined in patients with breast cancer receiving CHOP chemotherapy. This cytotoxic regimen caused a transient immunosuppression, maximal on day 14 of each cycle (P < 0.001); this was not cumulative during the four cycles of treatment. Those patients receiving L-arginine supplementation (30 g/day for 3 days prior to each course of chemotherapy) had a smaller and delayed onset of immunosuppression (day 14), compared with those patients who had CHOP only (day 9). L-Arginine was able to repeatedly stimulate NK and LAK cell cytotoxicity in patients who were receiving CHOP chemotherapy (P < 0.003). In conclusion further studies are required to determine the optimal use of chemotherapeutic agents, alone or in combination with immunostimulators, to avoid inhibition of host anti-cancer defence mechanisms.

AB - Certain cytotoxic drugs have been shown to suppress host anti-cancer defence mechanisms. The amino acid L-arginine can significantly enhance natural killer (NK) and lymphokine-activated killer (LAK) cell cytotoxicity in patients with locally advanced breast cancer. In this study, the effect of L-arginine supplementation on natural cytotoxicity was determined in patients with breast cancer receiving CHOP chemotherapy. This cytotoxic regimen caused a transient immunosuppression, maximal on day 14 of each cycle (P < 0.001); this was not cumulative during the four cycles of treatment. Those patients receiving L-arginine supplementation (30 g/day for 3 days prior to each course of chemotherapy) had a smaller and delayed onset of immunosuppression (day 14), compared with those patients who had CHOP only (day 9). L-Arginine was able to repeatedly stimulate NK and LAK cell cytotoxicity in patients who were receiving CHOP chemotherapy (P < 0.003). In conclusion further studies are required to determine the optimal use of chemotherapeutic agents, alone or in combination with immunostimulators, to avoid inhibition of host anti-cancer defence mechanisms.

KW - Antineoplastic agents

KW - Arginine

KW - Breast neoplasm

KW - Cytotoxicity (immunologic)

UR - http://www.scopus.com/inward/record.url?scp=0028015850&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 467

EP - 472

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 4

ER -